- Global Pharma News & Resources

Diabetic Neuropathic Pain Report - Pipeline Insights 2019 -

The "Diabetic Neuropathic Pain - Pipeline Insight, 2019" drug pipelines has been added to's offering.

"Diabetic Neuropathic Pain - Pipeline Insight, 2019 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Diabetic Neuropathic Pain development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Diabetic Neuropathic Pain

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Diabetic Neuropathic Pain

The report assesses the active Diabetic Neuropathic Pain pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report

  • The report provides a snapshot of the pipeline development for the Diabetic Neuropathic Pain
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Diabetic Neuropathic Pain
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Diabetic Neuropathic Pain
  • The report also covers the dormant and discontinued pipeline projects related to the Diabetic Neuropathic Pain

Companies Mentioned

  • Astellas Pharma Inc.
  • BioDelivery Sciences International Inc.
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Ltd.
  • Hydra Biosciences Inc.
  • Immune Pharmaceuticals Inc.
  • Laboratorios Del Dr. Esteve S.A.
  • Lohocla Research Corporation
  • Mertiva AB
  • Novaremed
  • PeriphaGen Inc.
  • Pharmaleads
  • Prismic Pharmaceuticals Inc.

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 25-Jan-2019